Compare HRMY & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | LMAT |
|---|---|---|
| Founded | 2017 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2020 | 2006 |
| Metric | HRMY | LMAT |
|---|---|---|
| Price | $35.34 | $96.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $44.11 | ★ $105.80 |
| AVG Volume (30 Days) | ★ 910.7K | 303.1K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | 7.97 | ★ 30.57 |
| EPS | 0.55 | ★ 0.68 |
| Revenue | ★ $868,453,000.00 | $249,602,000.00 |
| Revenue This Year | $19.75 | $14.21 |
| Revenue Next Year | $12.88 | $8.88 |
| P/E Ratio | ★ $65.09 | $143.37 |
| Revenue Growth | ★ 21.51 | 13.53 |
| 52 Week Low | $25.52 | $79.01 |
| 52 Week High | $40.87 | $118.01 |
| Indicator | HRMY | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 42.33 |
| Support Level | $35.05 | $95.47 |
| Resistance Level | $35.47 | $97.83 |
| Average True Range (ATR) | 1.59 | 3.46 |
| MACD | -0.20 | -0.58 |
| Stochastic Oscillator | 46.08 | 2.30 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.